Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: Role of cytochrome P450 isozymes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 11, 2012, Pages 1363-1375

  Kumar, Santosh ^a   Jin, Mengyao ^a   Ande, Anusha ^a   Sinha, Namita ^a   Silverstein, Peter S ^a   Kumar, Anil ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Alcohol; Antiretroviral; Cytochrome P450; HIV 1; NeuroAIDS

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ALCOHOL CONSUMPTION; ANTIVIRAL ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; CELL INFILTRATION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MONOCYTE; OXIDATIVE STRESS; PATHOGENESIS; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REVIEW; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALCOHOL DRINKING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; DRUG TOLERANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; ISOENZYMES; LIVER; OXIDATIVE STRESS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 84867566827     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.714366     Document Type: Review

References (102)

1. Global HIV/AIDS Response. Epidemic update and health sector progress towards Universal Access-Progress Report. World Health Organization; 2011. p. 11-47
2. Burgoyne RW, Tan DHS. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act. J Antimicrob Chemother 2008;61:469-73
3. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Ass 1998;279:450-4
4. May MT, Ingle SM. Life expectancy of HIV-positive adults: A review. Sex Health 2011;8:526-33
5. Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 2012;25:4-9
6. Vivithanaporn P, Gill MJ, Power C. Impact of current antiretroviral therapies on neuroAIDS. Expert Rev Anti Infect Ther 2011;9:371-4
7. Xia C, Luo D, Yu X, et al. HIV-associated dementia in the era of highly active antiretroviral therapy (HAART). Microbes Infect 2011; 13:419-25
8. Boissé L, Gill MJ, Power C. HIV infection of the central nervous system: Clinical features and neuropathogenesis. Neurol Clin 2008;26:799-819
9. Lucas S. Causes of death in the HAART era. Curr Opin Infect Dis 2012;25:36-41
10. Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011;44:102-10
11. Chander G. Addressing alcohol use in HIV-infected persons. Top Antivir Med 2011;19:143-7
12. Mehta SH, Lucas G, Astemborski J, et al. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007;19:637-45
13. Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care 2009; 21:655-63
14. Norman LR, Kumar A. Neuropsychological complications for HIV disease and substance of abuse. Am J Infec Dis 2006;2:115-24
15. Booth RE, Watters JK, Chitwood DD. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health 1993;83:1144-8
16. Hatfield LA, Horvath KJ, Jacoby SM, Simon BR. Comparison of substance use and risky sexual behavior among a diverse sample of urban, HIV-positive men who have sex with men. J Addict Dis 2009;28:208-18
17. Gonzalez A, Barinas J, O'Cleirigh C. Substance use: Impact on adherence and HIV medical treatment. Curr HIV/AIDS rep 2011;8:223-34
18. Chander G, Lau B, Moore R. Hazardous alcohol use: A risk factor for non-adherence and lack of suppression in HIV infection. J Ac Imm Def Syn 2006;43:411
19. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 Recommendations of an International AIDS Society-USA Panel. Clin Infec Dis 2008;47:266-85
20. Witteveen E, van Ameijden EJ. Drug users and HIV-combination therapy (HAART): factors which impede or facilitate adherence. Subst Use Misuse 2002;37:1905-25
21. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006;1:280-95
22. Silverstein PS, Shah A, Gupte R, et al. Methamphetamine toxicity and its implications during HIV-1 infection. J Neurovirol 2011;17:401-15
23. Kumar S. Role of cytochrome P450 systems in substance of abuse mediated HIV-1. Pathogenesis and NeuroAIDS. J Drug Metab Toxicol 2012;2:1-3
24. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47
25. Clemens DL, Mahan KJ. Alcoholic pancreatitis: lessons from the liver. World J Gastroenterol 2010;16:1314-20
26. Mellion M, Gilchrist JM, de la Monte S. Alcohol-related peripheral neuropathy: nutritional, toxic, or both? Muscle Nerve 2011;43:309-16
27. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002;63:179-86
28. Miguez MJ, Shor-Posner G, Morales G, et al. HIV treatment in drug abusers: Impact of alcohol use. Addict Biol 2003;8:33-7
29. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: Review and meta-analysis. J Acquir Immune Defic Syndr 2009;52:180-202
30. Ferrari LF, Levine JD. Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. Eur J Neurosci 2010;32:811-18
31. Belmadani A, Neafsey EJ, Collins MA. Human immunodeficiency virus type 1 gp120 and ethanol coexposure in rat organotypic brain slice cultures: Curtailment of gp120-induced neurotoxicity and neurotoxic mediators by moderate but not high ethanol concentrations. J Neurovirol 2003;9:45-54
32. Shacham E, Agbebi A, Stamm K, Overton ET. Alcohol consumption is associated with poor health in HIV clinic patient population: A behavioral surveillance study. AIDS Behav 2011;15:209-13
33. Acheampong E, Mukhtar M, Parveen Z, et al. Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cells. Virology 2002;304:222-34
34. Persidsky Y, Ho W, Ramirez SH, et al. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun 2011;25:61-70
35. Bagasra O, Bachman SE, Jew L, et al. Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: Potential immunopathogenic mechanisms. J Infect Dis 1996; 173:550-8
36. Bagasra O, Kajdacsy-Balla A, Lischner HW, Pomerantz RJ. Alcohol intake increases human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells. J Infect Dis 1993;167:789-97
37. Haorah J, Heilman D, Diekmann C, et al. Alcohol and HIV decrease proteasome and immunoproteasome function in macrophages: Implications for impaired immune function during disease. Cell Immunol 2004;229:139-48
38. Kumar R, Perez-Casanova AE, Tirado G, et al. Increased viral replication in simian immunodeficiency virus/simian-HIVinfected macaques with self-administering model of chronic alcohol consumption. J Acquir Immune Defic Syndr 2005;39:386-90
39. Marcondes MC, Watry D, Zandonatti M, et al. Chronic alcohol consumption generates a vulnerable immune environment during early SIV infection in rhesus macaques. Alcohol Clin Exp Res 2008;32:1583-92
40. Baum MK, Rafie C, Lai S, et al. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 2010; 26:511-18
41. Buckner CM, Luers AJ, Calderon TM, et al. Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. J Neuroimmune Pharmacol 2006;1:160-81
42. Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem 2002;9:1893-903
43. Cobos-Jime'nez V, Booiman T, Hamann J, Kootstra NA. Macrophages and HIV-1. Curr Opin HIV AIDS 2011;6:385-90
44. Kramer-Hämmerle S, Rothenaigner I, Wolff H, et al. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005;111:194-213
45. Pfefferbaum A, Rosenbloom MJ, Rohlfing T, et al. Contribution of alcoholism to brain dysmorphology in HIV infection: Effects on the ventricles and corpus callosum. Neuroimage 2006;33:239-51
46. Pfefferbaum A, Rosenbloom MJ, Sassoon SA, et al. Regional brain structural dysmorphology in human immunodeficiency virus infection: Effects of acquired immune deficiency syndrome, alcoholism, and age. Biol Psychiatry 2012;Published online march 26, 2012; doi:10.1016/j. biopsych.2012.02.018
47. Rothlind JC, Greenfield TM, Bruce AV, et al. Heavy alcohol consumption in individuals with HIV infection: Effects on neuropsychological performance. J Int Neuropsychol Soc 2005;11:70-83
48. Haorah J, Knipe B, Leibhart J, et al. Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. J Leukoc Biol 2005;78:1223-32
49. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010;85:1-18
50. Neblett RC, Hutton HE, Lau B, et al. Alcohol consumption among HIV-infected women: Impact on time to antiretroviral therapy and survival. J Womens Health (Larchmt) 2011;20:279-86
51. Perno CF, Newcomb FM, Davis DA, et al. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 1998;178:413-22
52. Perno CF, Balestra E, Francesconi M, et al. Antiviral profile of HIV inhibitors in macrophages: Implications for therapy. Curr Top Med Chem 2004;4:1009-15
53. Aquaro S, Svicher V, Schols D, et al. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol 2006;80:1103-10
54. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: Implication for HIV eradication. Antivir Chem Chemother 2009;20:63-78
55. Gonzalez FJ. The 2006 bernard B. Brodie award lecture: CYP2E1. Drug Metab Dispos 2007;35:1-8
56. Millonig G, Wang Y, Homann N, et al. Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions. Int J Cancer 2011;128:533-40
57. Jing L, Jin CM, Li SS, et al. Chronic alcohol intake-induced oxidative stress and apoptosis: Role of CYP2E1 and calpain-1 in alcoholic cardiomyopathy. Mol Cell Biochem 2012;359:283-92
58. Tang H, Sebastian BM, Axhemi A, et al. Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res 2012;36:214-22
59. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch toxicol 2009;83:519-48
60. Marichalar-Mendia X, Rodriguez-Tojo MJ, Acha-Sagredo A, et al. Oral cancer and polymorphism of ethanol metabolising genes. Oral Oncol 2010;46:9-13
61. Karamanakos PN, Trafalis DT, Geromichalos GD, et al. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1- (3-pyridyl)-1-butanone (NNK)-induced mutagenicity. Hum Retroviruses 2006;22:589-94
62. Bishayee A, Darvesh AS, Politis T, McGory R. Resveratrol and liver disease: from bench to bedside and community. Liver Int 2010;8:1103-14
63. Hutson JL, Wickramasinghe SN. Expression of CYP2E1 by human monocyte-derived macrophages. J Pathol 1999;188:197-200
64. Jin M, Arya P, Patel K, et al. Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcohol Clin Exp Res 2011;35:132-9
65. Aquaro S, Muscoli C, Ranazzi A, et al. The contribution of peroxynitrite generation in HIV replication in human primary macrophages. Retrovirology 2007;4:74-6
66. Mialocq P, Oiry J, Puy JY, et al. Oxidative metabolism of HIV-infected macrophages: The role of glutathione and a pharmacologic approach. Pathol Biol (Paris) 2001;49:567-71
67. McCartney EM, Beard MR. Impact of alcohol on hepatitis C virus replication and interferon signaling. World J Gastroenterol 2010;16:1337-43
68. Malaplate-Armand C, Leininger-Muller B, Batt AM. Astrocytic cytochromes p450: An enzyme subfamily critical for brain metabolism and neuroprotection. Rev Neurol (Paris) 2004;160:651-8
69. Ande A, Earla R, Jin M, et al. An LCMS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes. Drug Alcohol Depend 2012;published online April 10, 2012; doi.10.1016/j.drugalcdep.2012.03.015
70. Haorah J, Ramirez SH, Floreani N, et al. Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radic Biol Med 2008;45:1542-50
71. Howard LA, Miksys S, Hoffmann E, et al. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003;138:1376-86
72. Jin M, Kumar A, Kumar S. CYP2E1-mediated alcohol metabolism induces expression of CYP2A6 and CYP2E1 through oxidative stress-induced PKC signaling cascades in monocytes and astrocytes. J Neuroimmune Pharmacol 2012;7:S41
73. Hamitouche S, Poupon J, Dreano Y, et al. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: Role of CYP2C isoforms in human liver microsomes. Toxicol Lett 2006;167:221-30
74. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115
75. Jin M, Kumar A, Kumar S. Ethanol-Mediated Regulation of Cytochrome P450 2A6 Expression in Monocytes: Role of Oxidative Stress-Mediated PKC/MEK/Nrf2 Pathway. PLoS ONE 2012;7:e35505-12
76. Jin M, Earla R, Shah A, et al. A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: Implications in oxidative stress in HIV+smokers. J Neuroimmune Pharmacol 2012;7:289-99
77. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 2007;3:583-98
78. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006;1:323-39
79. Pal D, Kwatra D, Minocha M, et al. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci 2011;88:959-71
80. Lu C, Balani SK, Qian MG, et al. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist. J Pharmacol Exp Ther 2010;332:562-8
81. Xu Y, Zhou Y, Hayashi M, et al. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos 2011;39:1139-48
82. Feierman DE, Melinkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res 2003;27:981-8
83. Ghosh C, Marchi N, Desai NK, et al. Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia 2011;52:562-71
84. Kumar S, Earla R, Jin M, et al. Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir. Biochem Biophys Res Commun 2010;402:163-7
85. Kumar S, Kumar A. Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. Alcohol Clin Exp Res 2011;35:2121-7
86. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002;18:757-70
87. Flexner CW, Cargill VA, Sinclair J, et al. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDS 2001;15:57-8
88. Kalichman SC, Amaral CM, White D, et al. Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDS 2009;23:449-54
89. Shibata N, Kageyama M, Kishida T, et al. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. Biopharm Drug Dispos 2003;24:335-44
90. Shibata N, Kageyama M, Kimura K, et al. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats. Biol Pharm Bull 2004;27:203-9
91. Scopelliti F, Pollicita M, Ceccherini-Silberstein F, et al. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res 2011;92:255-61
92. Talakad JC, Kumar S, Halpert Jr. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 2008;37:644-50
93. Tian G, Ghanekar SV, Aharony D, et al. Multiple inhibitor binding sites for transition statae analogs and small molecule inhibitors. J Biol Chem 2005;278:28968-75
94. Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 2010;125:230-48
95. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70
96. Croxtall JD, Perry CM. Lopinavir/Ritonavir: A review of its use in the management of HIV-1 infection. Drugs 2010;70:1885-915
97. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007;21:1449-55
98. Brogan AJ, Mrus J, Hill A, et al. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials 2010;11:133-44
99. von Weymarn LB, Chun JA, Hollenberg PF. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: Potential for chemoprevention in smokers. Carcinogenesis 2006;27:782-90
100. Diedrich CR, Flynn JL. HIV-1/mycobacterium tuberculosis coinfection immunology: How does HIV-1 exacerbate tuberculosis? Infect Immun 2011;79:1407-17
101. Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol 2011;Published online Dec 27, 2010; doi:10.1155/2011/103917
102. Patel N, Talwar A, Reichert VC, et al. Tobacco and HIV. Clin Occup Environ Med 2006;5:193-207